HOME >> BIOLOGY >> NEWS
The PSA bounce Does it have clinical significance?

Using the largest known prostate cancer data set of patients treated solely with external-beam radiation in the U.S., radiation oncologists have examined the "PSA bounce" phenomenon and determined that it is not an indicator that men will die of prostate cancer any sooner than those men who do not experience a bounce. That is the result of a multi-institutional analysis presented today at the 46th Annual Meeting of the American Society for Therapeutic Radiology and Oncology in Atlanta, Ga.

The PSA (prostate-specific antigen) test is a blood test used for routine prostate cancer screening. The "PSA bounce" is a rise and then decline in the PSA level following radiation treatment for prostate cancer. The bounce phenomenon occurs in a third to half of men treated with radiation for prostate cancer. Urologists, radiation and medical oncologists have struggled with what a bouncing PSA means for a patient's prognosis, and how or if to offer further treatment.

"Because a steady rise in PSA can mean that cancer has recurred, physicians often interpret a bounce as the possibility that the cancer may still exist after treatment," explained Eric M. Horwitz, M.D., clinical director of the radiation oncology department at Fox Chase Cancer Center and lead author of the study. "Some physicians prescribe hormonal therapy in this situation, but hormones can have significant side effects for the patient, and may not be clinically necessary. For these reasons, it's important to develop clear guidelines."

In this retrospective analysis, data were gathered from the records of 4,839 men treated only with external-beam radiation between 1986 and 1995 at nine institutions throughout the US. The median follow-up was 6.3 years. Treatment during this time period consisted primarily of conventional radiation therapy, a lower dose than is generally used at academic cancer centers today, although some patients were treated with 3D conformal radiation therapy. In thi
'"/>

Contact: Colleen Kirsch
colleen.kirsch@fccc.edu
215-306-1211
Fox Chase Cancer Center
6-Oct-2004


Page: 1 2

Related biology news :

1. HIV-1 kills immune cells in the gut that may never bounce back
2. Phytoplankton bounce back from abrupt climate change
3. Fat kids can bounce back to normal blood pressure
4. Preclinical study links gene to brain aneurysm formation
5. Gene variant is associated with brain anatomy, clinical course of ADHD
6. New joint replacement material developed at MGH put to first clinical use
7. Serica scientists win AOSSM Award for ACL (knee) tissue regeneration in preclinical study
8. From clinical cancer research: rethinking therapeutic cancer vaccine trials
9. Manganese levels increase in scrapie-infected sheep before clinical symptoms develop
10. Biovest announces interim blinded data of fast-tracked pivotal Phase 3 clinical trial of BiovaxID
11. Alzheimers drug based on Purdue -- designed inhibitor begins clinical trials

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: The PSA bounce Does have clinical significance

(Date:1/22/2015)... , Jan. 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ... in general the State of Washington,s ... a new enrollment and central issuance system for driver,s licenses ... The project planning and development will start in January ...
(Date:1/22/2015)... MADISON, Wis. , Jan. 15, 2015  BellBrook ... for drug discovery, announced the launch of a ... of the company,s Transcreener UDP Assay, a high ... enzymes. The new assay will allow for sensitive ...
(Date:1/22/2015)... YORK , Jan. 21, 2015  Analyst Report Issued by ... Card Brands report showed that planet-wide, transactions at merchants on ... while the total number of credit, debit, and prepaid cards ... U.S. were victims of fraudulent card usage in 2012, and ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
(Date:12/24/2014)... BOSTON, MA (PRWEB) December 23, 2014 ... series is designed to introduce cutting edge communication ... partners of platform upgrades. This webinar series demonstrates ... their quest to leverage web conferencing’s most innovative ...
(Date:12/24/2014)... New York (PRWEB) December 23, 2014 According ... the Long Island Affiliate of ITRA Global, the national office ... but steady recovery. This is evidenced by the third ... strong stock market. Low energy costs have held inflation ...
(Date:12/24/2014)... Nashville Fertility Center announced that Dr. George ... for Reproductive Medicine (ASRM), a leading professional organization committed to ... new role as treasurer, Dr. Hill also fills a seat ... furthering the mission of ASRM. , Dr. Hill has ...
(Date:12/24/2014)... December 23, 2014 Pipette.com announces their ... can submit their #HolidayInTheLab pictures for a chance to win ... those struggling to think of a holiday gift for their ... provides the ideal holiday presents. The #HolidayInTheLab Contest encourages ...
Breaking Biology Technology:SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2
Cached News: